PT3220891T - Formulação sublingual de riluzol - Google Patents
Formulação sublingual de riluzolInfo
- Publication number
- PT3220891T PT3220891T PT158234153T PT15823415T PT3220891T PT 3220891 T PT3220891 T PT 3220891T PT 158234153 T PT158234153 T PT 158234153T PT 15823415 T PT15823415 T PT 15823415T PT 3220891 T PT3220891 T PT 3220891T
- Authority
- PT
- Portugal
- Prior art keywords
- riluzole
- sublingual formulation
- sublingual
- formulation
- Prior art date
Links
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 229960004181 riluzole Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462083094P | 2014-11-21 | 2014-11-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3220891T true PT3220891T (pt) | 2019-10-31 |
Family
ID=55085882
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT158234153T PT3220891T (pt) | 2014-11-21 | 2015-11-17 | Formulação sublingual de riluzol |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US11660267B2 (enExample) |
| EP (3) | EP3220891B1 (enExample) |
| JP (3) | JP6753860B2 (enExample) |
| KR (2) | KR102811263B1 (enExample) |
| CN (1) | CN107249567B (enExample) |
| AU (2) | AU2015350148B2 (enExample) |
| BR (1) | BR112017010423B1 (enExample) |
| CA (1) | CA2967662A1 (enExample) |
| CY (1) | CY1122469T1 (enExample) |
| DK (1) | DK3220891T3 (enExample) |
| EA (1) | EA038518B1 (enExample) |
| ES (2) | ES2751300T3 (enExample) |
| HR (1) | HRP20191892T8 (enExample) |
| HU (1) | HUE046869T2 (enExample) |
| IL (2) | IL278188B2 (enExample) |
| LT (1) | LT3220891T (enExample) |
| MX (1) | MX368838B (enExample) |
| PH (1) | PH12017500934B1 (enExample) |
| PL (1) | PL3220891T3 (enExample) |
| PT (1) | PT3220891T (enExample) |
| RS (1) | RS59490B1 (enExample) |
| SG (1) | SG11201703896QA (enExample) |
| SI (1) | SI3220891T1 (enExample) |
| WO (1) | WO2016081472A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111892577B (zh) | 2016-10-11 | 2023-07-07 | 阿尔维纳斯运营股份有限公司 | 用于雄激素受体靶向降解的化合物和方法 |
| BR112020016256A2 (pt) * | 2018-02-21 | 2020-12-15 | AI Therapeutics, Inc. | Terapia de combinação com apilimod e agentes gluta-matérgicos |
| JP2021525714A (ja) * | 2018-05-27 | 2021-09-27 | バイオヘイブン・ファーマシューティカル・ホールディング・カンパニー・リミテッドＢｉｏｈａｖｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｈｏｌｄｉｎｇ Ｃｏｍｐａｎｙ Ｌｔｄ． | 疾患の処置のためのリルゾール口腔内崩壊錠の使用 |
| EA202190544A1 (ru) * | 2018-08-16 | 2021-06-18 | Биохэйвен Терапьютикс Лтд. | Применение распадающихся в полости рта таблеток рилузола для лечения заболеваний |
| KR20220087482A (ko) * | 2019-10-22 | 2022-06-24 | 아비나스 오퍼레이션스, 인코포레이티드 | 전립선암 치료 방법 |
| JP2023524599A (ja) | 2020-05-09 | 2023-06-12 | アルビナス・オペレーションズ・インコーポレイテッド | 二官能性化合物を製造する方法、二官能性化合物の超高純度形態、及びそれらを含む剤形 |
| EP4240308A4 (en) * | 2020-10-05 | 2024-10-30 | Icahn School of Medicine at Mount Sinai | Riluzole for the treatment of alzheimer's disease |
| US11672761B2 (en) | 2020-11-16 | 2023-06-13 | Orcosa Inc. | Rapidly infusing platform and compositions for therapeutic treatment in humans |
| EP4243602A4 (en) | 2020-11-16 | 2024-11-13 | Orcosa Inc. | Improved use of cannabinoids in the treatment of alzheimer's disease |
| CN113876735B (zh) * | 2021-10-20 | 2023-05-12 | 陇南市第一人民医院 | 一种利鲁唑微球制剂及其制备方法 |
| KR102625977B1 (ko) | 2021-11-24 | 2024-01-17 | 부산대학교 산학협력단 | 리루졸을 유효성분으로 포함하는 염증성 장질환 예방 또는 치료용 조성물 |
| US12496301B2 (en) | 2023-12-08 | 2025-12-16 | Arvinas Operations, Inc. | Use of androgen receptor degrader for the treatment of spinal and bulbar muscular atrophy |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2492258A1 (fr) * | 1980-10-17 | 1982-04-23 | Pharmindustrie | Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole |
| FR2702148B1 (fr) * | 1993-03-05 | 1995-04-07 | Rhone Poulenc Rorer Sa | Application d'anticonvulsivants dans le traitement du neuro-sida. |
| JP3233638B2 (ja) | 1993-07-09 | 2001-11-26 | アール．ピー． シェーラー コーポレイション | 凍結乾燥された薬投与形状物の製造方法 |
| US5457895A (en) | 1993-10-01 | 1995-10-17 | R. P. Scherer Corporation | Method of identifying freeze-dried dosage forms |
| US5837287A (en) * | 1994-10-28 | 1998-11-17 | R P Scherer Corporation | Process for preparing solid pharmaceutical dosage forms |
| ES2212816T3 (es) * | 1996-12-20 | 2004-08-01 | NUTRINOVA NUTRITION SPECIALTIES & FOOD INGREDIENTS GMBH | Procedimiento para el refuerzo del poder edulcorante y para el mejoramiento del sabor de una mezcla de materiales edulcorantes muy intensos. |
| AU736912B2 (en) | 1997-02-20 | 2001-08-02 | Therics, Inc. | Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same |
| AU8977698A (en) | 1997-07-25 | 1999-02-16 | Elan Corporation, Plc | A process for the preparation of a granulate suitable to the preparation of rapidly disintegrable mouth-soluble tablets |
| HUP0105089A3 (en) | 1998-11-20 | 2002-09-30 | Skyepharma Canada Inc | Compositions containing the active ingredient in form dispersible phospholipid stabilized microparticles |
| WO2000033814A2 (en) | 1998-12-09 | 2000-06-15 | Chiron Corporation | Method for administering agents to the central nervous system |
| FR2787028B1 (fr) * | 1998-12-15 | 2002-10-18 | Aventis Pharma Sa | Utilisation du riluzole dans le traitement des traumatismes acoustiques |
| US6284270B1 (en) | 1999-08-04 | 2001-09-04 | Drugtech Corporation | Means for creating a mass having structural integrity |
| US6316029B1 (en) | 2000-05-18 | 2001-11-13 | Flak Pharma International, Ltd. | Rapidly disintegrating solid oral dosage form |
| JP2001328947A (ja) * | 2000-05-19 | 2001-11-27 | Ritsuko Senba | 脳由来神経栄養因子発現促進剤 |
| US6432992B1 (en) * | 2000-06-05 | 2002-08-13 | Aventis Pharm Sa | Use of riluzole or its salts for the prevention and treatment of adrenoleukodystrophy |
| WO2003079972A2 (en) * | 2002-02-22 | 2003-10-02 | New River Parmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
| US6982251B2 (en) | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
| US6814978B2 (en) | 2000-12-29 | 2004-11-09 | Mcneil-Ppc, Inc. | Process for preparing a soft tablet |
| US6509040B1 (en) | 2001-06-22 | 2003-01-21 | R.P. Scherer Corporation | Fast dispersing dosage forms essentially free of mammalian gelatin |
| DK1443912T3 (da) | 2001-10-12 | 2008-01-21 | Elan Pharma Int Ltd | Sammensætninger med en kombination af umiddelbare og kontrollerede frisætningsegenskaber |
| CA2476250C (en) | 2002-02-13 | 2010-08-03 | Michael K. Weibel | Drug dose-form and method of manufacture |
| WO2004105756A2 (en) * | 2003-05-29 | 2004-12-09 | Novartis Ag | Combination comprising (a) a neuroprotecting agent and (b) an agent binding to gadph and pharmaceutical use thereof |
| US7282217B1 (en) | 2003-08-29 | 2007-10-16 | Kv Pharmaceutical Company | Rapidly disintegrable tablets |
| WO2005084377A2 (en) * | 2004-03-03 | 2005-09-15 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and riluzole |
| US8158152B2 (en) | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
| JP2009521523A (ja) | 2005-12-27 | 2009-06-04 | ジュビラント・オルガノシス・リミテッド | 口中溶解性医薬組成物およびその製造方法 |
| GB0625322D0 (en) * | 2006-12-19 | 2007-01-24 | Pharmakodex Ltd | Pharmaceutical compositions |
| EP1980240A1 (en) * | 2007-04-11 | 2008-10-15 | Cephalon France | Lyophilized pharmaceutical compositions and methods of making and using same |
| CN101686942B (zh) | 2007-06-27 | 2012-09-26 | 韩美药品株式会社 | 用于快速制备用于口服的崩解剂的方法及其产品 |
| US20110183942A1 (en) * | 2008-07-15 | 2011-07-28 | University Of Medicine And Dentistry Of New Jersey | Methods and Compositions for Treating Alzheimer's Disease |
| US8788212B2 (en) | 2008-10-31 | 2014-07-22 | The Invention Science Fund I, Llc | Compositions and methods for biological remodeling with frozen particle compositions |
| US8518031B2 (en) | 2008-10-31 | 2013-08-27 | The Invention Science Fund I, Llc | Systems, devices and methods for making or administering frozen particles |
| WO2010096869A1 (en) * | 2009-02-26 | 2010-09-02 | Steven Michael Weiss | An agent for improving inotropy and lusitropy, and for treating diseases causing or caused by poor contractility or relaxation of the heart |
| EP2228054A1 (en) | 2009-03-13 | 2010-09-15 | ITALFARMACO S.p.A. | Riluzole aqueous suspensions |
| US8313768B2 (en) | 2009-09-24 | 2012-11-20 | Mcneil-Ppc, Inc. | Manufacture of tablet having immediate release region and sustained release region |
| US9241933B2 (en) | 2011-03-01 | 2016-01-26 | Pharnext | Compositions for treating amyotrophic lateral sclerosis |
| PT2560631E (pt) * | 2011-03-01 | 2014-02-24 | Pharnext | Terapia à base de baclofeno e acamprosato de distúrbios neurológicos |
| UA115968C2 (uk) | 2011-03-01 | 2018-01-25 | Фарнекст | Нові композиції для лікування неврологічних захворювань |
| US10272082B2 (en) * | 2011-07-13 | 2019-04-30 | Cytokinetics, Inc. | Combination ALS therapy |
| CA3075331A1 (en) * | 2012-03-01 | 2013-09-06 | Pharnext | New compositions for treating amyotrophic lateral sclerosis |
| EP3220890A1 (en) | 2014-11-21 | 2017-09-27 | Biohaven Pharmaceutical Holding Company Ltd. | Sublingual administration of riluzole |
| DK3265448T3 (da) * | 2015-03-03 | 2022-03-28 | Biohaven Therapeutics Ltd | Riluzol-prodrugs og anvendelse deraf |
-
2015
- 2015-11-17 EA EA201790958A patent/EA038518B1/ru unknown
- 2015-11-17 HU HUE15823415A patent/HUE046869T2/hu unknown
- 2015-11-17 CA CA2967662A patent/CA2967662A1/en active Pending
- 2015-11-17 EP EP15823415.3A patent/EP3220891B1/en active Active
- 2015-11-17 PT PT158234153T patent/PT3220891T/pt unknown
- 2015-11-17 EP EP19186196.2A patent/EP3616686B8/en active Active
- 2015-11-17 AU AU2015350148A patent/AU2015350148B2/en active Active
- 2015-11-17 CN CN201580073630.4A patent/CN107249567B/zh active Active
- 2015-11-17 BR BR112017010423-7A patent/BR112017010423B1/pt active IP Right Grant
- 2015-11-17 SG SG11201703896QA patent/SG11201703896QA/en unknown
- 2015-11-17 KR KR1020237031525A patent/KR102811263B1/ko active Active
- 2015-11-17 EP EP21169884.0A patent/EP4039247B1/en active Active
- 2015-11-17 ES ES15823415T patent/ES2751300T3/es active Active
- 2015-11-17 JP JP2017545858A patent/JP6753860B2/ja active Active
- 2015-11-17 LT LT15823415T patent/LT3220891T/lt unknown
- 2015-11-17 ES ES19186196T patent/ES2882783T3/es active Active
- 2015-11-17 US US15/100,160 patent/US11660267B2/en active Active
- 2015-11-17 PL PL15823415T patent/PL3220891T3/pl unknown
- 2015-11-17 HR HRP20191892TT patent/HRP20191892T8/hr unknown
- 2015-11-17 IL IL278188A patent/IL278188B2/en unknown
- 2015-11-17 RS RS20191376A patent/RS59490B1/sr unknown
- 2015-11-17 MX MX2017006446A patent/MX368838B/es active IP Right Grant
- 2015-11-17 DK DK15823415T patent/DK3220891T3/da active
- 2015-11-17 WO PCT/US2015/061114 patent/WO2016081472A1/en not_active Ceased
- 2015-11-17 KR KR1020177016906A patent/KR102580378B1/ko active Active
- 2015-11-17 PH PH1/2017/500934A patent/PH12017500934B1/en unknown
- 2015-11-17 SI SI201530956T patent/SI3220891T1/sl unknown
-
2017
- 2017-05-15 IL IL252285A patent/IL252285B/en active IP Right Grant
-
2019
- 2019-10-22 CY CY20191101095T patent/CY1122469T1/el unknown
-
2020
- 2020-08-20 JP JP2020139429A patent/JP2021001173A/ja active Pending
- 2020-10-25 US US17/079,498 patent/US12121609B2/en active Active
-
2021
- 2021-02-17 AU AU2021201034A patent/AU2021201034B2/en active Active
-
2023
- 2023-02-03 JP JP2023015640A patent/JP2023065398A/ja active Pending
-
2024
- 2024-10-21 US US18/921,046 patent/US20250114301A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL278188A (en) | Sublingual formulation of riluzole | |
| IL250089A0 (en) | Metrology of multiple sampling processes | |
| SG11201609265RA (en) | Characterizing states of subject | |
| IL252283A0 (en) | Sublingual administration of riluzole | |
| PL3102555T3 (pl) | Kompozycje związków i ich zastosowania | |
| SI3154526T1 (sl) | Trdne oblike sofosbuvira | |
| ZA201700022B (en) | A novel formulation of meloxicam | |
| IL246979A0 (en) | Crystalline forms of sofosbuvir | |
| GB201407822D0 (en) | Use of a composition | |
| IL249130B (en) | Preparation of piperidine-4-carbothioamide | |
| GB2544217B (en) | Chlorination of sucrose-6-esters | |
| IL249332A0 (en) | Crystalline forms of sofosbuvir | |
| HK1242593A1 (en) | Sublingual administration of riluzole | |
| GB201412359D0 (en) | Composition of objects | |
| GB201412089D0 (en) | Composition of objects | |
| GB201418410D0 (en) | use of compositions of matter | |
| GB201418230D0 (en) | Construction of surfaces | |
| HUP1400294A2 (hu) | Clopidogrel új alkalmazása | |
| GB201417347D0 (en) | Prodrugs of delanzomib | |
| GB201417348D0 (en) | Prodrugs of lxazomib | |
| GB201405157D0 (en) | Theory of international law | |
| GB201405142D0 (en) | Theory of restoration | |
| GB201404705D0 (en) | Theory of Conceptual art | |
| TWM489614U (en) | Structure of bathroom accessory | |
| GB201405158D0 (en) | Theory of european law |